GlaxoSmithKline: Infections trials

The registry lists 163 Infections studies with GlaxoSmithKline as lead sponsor. 1 are open to participants now and 57 have results posted.

Phase 1 85Phase 2 29Phase 3 27Phase 4 10No phase 13(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult SubjectsCompletedNCT01967771Phase 1
• Single Dose Escalation Study of GSK2838232 in Healthy SubjectsCompletedNCT01802918Phase 1
• An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving MaravirocNo longer availableNCT01776996
• A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult SubjectsCompletedNCT01762995Phase 1
• A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy SubjectsCompletedNCT01756131Phase 1
• A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult SubjectsCompletedNCT01754116Phase 1
• Relative Bioavailability Study of GSK1265744 FormulationsCompletedNCT01648257Phase 1
• Evaluation of the Bioequivalence of a Combined Formulated TabletCompletedNCT01622790Phase 1
• Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV DosesCompletedNCT01615796Phase 1
• A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™CompletedNCT01597648Phase 1
• A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult SubjectsCompletedNCT01593046Phase 1
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057CompletedNCT01587807Phase 1
• A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).CompletedNCT01563328Phase 1
• Dolutegravir Expanded Access StudyCompletedNCT01536873Not applicable
• Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and EthinylestradiolCompletedNCT01498861Phase 1
• A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult SubjectsCompletedNCT01467531Phase 1
• Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.CompletedNCT01467518Phase 1
• Drug Interaction Study Between Dolutegravir and PrednisoneCompletedNCT01425099Phase 1
• Relative Bioavailability Study of a Pediatric Granule Formulation of DolutegravirCompletedNCT01382238Phase 1
• Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination TabletsCompletedNCT01366547Phase 1
• Dolutegravir Renal Impairment StudyCompletedNCT01353716Phase 1
• A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese SubjectsCompletedNCT01332565Phase 1
• A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.WithdrawnNCT01283100Phase 1
• A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult SubjectsWithdrawnNCT01273103Phase 1
• Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female VolunteersCompletedNCT01231542Phase 1
• GSK1349572 Hepatic Impairment StudyCompletedNCT01231529Phase 1
• A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy SubjectsCompletedNCT01214993Phase 1
• A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435CompletedNCT01209117Phase 1
• GSK1349572 Drug Interaction Study With Fosamprenavir/RitonavirCompletedNCT01209065Phase 1
• ZIAGEN® Post-marketing SurveillanceCompletedNCT01205243
• A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.TerminatedNCT01195974Phase 1
• A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.CompletedNCT01138072Phase 1
• A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult SubjectsCompletedNCT01101893Phase 1
• GSK1349572 Drug Interaction Study With EfavirenzCompletedNCT01098526Phase 1
• GSK1349572 Relative Bioavailability StudyCompletedNCT01098513Phase 1
• PENTA Fosamprenavir StudyCompletedNCT01077635
• Fractures Stratified by HIV and Antiretroviral Therapy (ART) StatusCompletedNCT01077557
• Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy VolunteersCompletedNCT01068925Phase 1
• HIV Treatment and CVD EventsCompletedNCT01054638
• A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761CompletedNCT01031472Phase 1
• DDI Study of Etravirine and GSK1265744CompletedNCT00920296Phase 1
• Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe DrugsCompletedNCT00920088Phase 1
• Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.CompletedNCT00812318Phase 1
• GSK1349572 Drug Interaction Study With Protease InhibitorsCompletedNCT00774735Phase 1
• GSK706769/KALETRA Drug-drug Interaction StudyCompletedNCT00723775Phase 1
• GSK706769 Repeat Dose StudyCompletedNCT00711386Phase 1
• Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected PatientsCompletedNCT00481390
• Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701CompletedNCT00453440
• Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected PatientsCompletedNCT00441688Phase 4
• Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected AdultsCompletedNCT00398125Phase 2
• A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.CompletedNCT00386347Phase 1
• AUGMENTIN 1gm In Skin And Soft Tissue InfectionCompletedNCT00343135Phase 4
• GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected AdultsCompletedNCT00257621Phase 2
• A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced AdultsTerminatedNCT00242879Phase 2
• Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)CompletedNCT00242840Phase 3
• Fosamprenavir Expanded AccessCompletedNCT00240552Phase 4
• GW873140 In Combination With Combivir In HIV Infected SubjectsTerminatedNCT00104429Phase 2
• GW873140 In Combination With Kaletra In HIV Infected SubjectsTerminatedNCT00102778Phase 2
• Fosamprenavir Versus Other Protease InhibitorsCompletedNCT00094523Phase 3
• KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 WeeksCompletedNCT00085943Phase 3
• A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIVCompletedNCT00082394Phase 4
• A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced PatientsCompletedNCT00046176Phase 3
• New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected SubjectsCompletedNCT00044577Phase 3